Leishmania recombinant polyprotein (KSAC) (KSAC)

The Leishmania recombinant polyprotein is a synthetic fusion protein designed as a multi-antigen vaccine candidate to provide protection against various forms of leishmaniasis, including visceral, cutaneous, and mucocutaneous types (Coler et al., 2002; Goto et al., 2011). These polyproteins, such as Leish-F1 and KSAC, are engineered by fusing several highly conserved and immunogenic parasite proteins—such as TSA, LmSTI1, LeIF, KMP11, SMT, A2, and CPB—into a single polypeptide chain to broaden the immune response (Reed et al., 2008). The primary biological function of these constructs is to serve as a target for the host's immune system, specifically stimulating a robust Th1-type cellular immune response. This response is characterized by the activation of CD4+ T cells and the production of pro-inflammatory cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor (TNF), which are essential for activating macrophages to destroy intracellular Leishmania amastigotes (Duthie et al., 2012). In clinical development, these polyproteins are typically formulated with adjuvants like GLA-SE to enhance their immunogenicity and protective efficacy (ClinicalTrials.gov NCT00637169). While they are not traditional drug targets for small molecule inhibition, they represent the primary molecular focus for current immunotherapeutic and prophylactic vaccine strategies against Leishmania infection.

Other names

Leish-F1Leish-F2Leish-F3KSACLeishmania fusion proteinML700LRV1 polyprotein

Stimulates a Th1-biased cell-mediated immune response by presenting multiple conserved Leishmania antigens to the immune system, leading to the activation of CD4+ and CD8+ T cells and the production of protective cytokines like IFN-gamma.